Bank Julius Baer & Co
CRSP icon

Bank Julius Baer & Co’s CRISPR Therapeutics CRSP Stock Holding History

Bank Julius Baer & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$740K Buy
13,178
+326
+3% +$17.2K ﹤0.01% 424
2026
Q1 		$611K Sell
12,852
-959
-7% -$50.6K ﹤0.01% 422
2025
Q4 		$724K Buy
13,811
+984
+8% +$58.9K ﹤0.01% 396
2025
Q3 		$831K Buy
12,827
+8,192
+177% +$470K ﹤0.01% 383
2025
Q2 		$225K Sell
4,635
-838
-15% -$32.4K ﹤0.01% 437
2025
Q1 		$186K Buy
5,473
+612
+13% +$25.9K ﹤0.01% 428
2024
Q4 		$211K Buy
+4,861
New +$230K ﹤0.01% 422
2024
Q2 		– Sell
-130
Closed -$8.86K – 503
2024
Q1 		$8.86K Hold
130
– – ﹤0.01% 514
2023
Q4 		$8.14K Sell
130
-19,726
-99% -$1.09M ﹤0.01% 527
2023
Q3 		$901K Buy
19,856
+13,417
+208% +$693K 0.01% 267
2023
Q2 		$361K Buy
6,439
+5,137
+395% +$291K ﹤0.01% 369
2023
Q1 		$59K Buy
1,302
+345
+36% +$16.8K ﹤0.01% 512
2022
Q4 		$39K Sell
957
-14,499
-94% -$769K ﹤0.01% 516
2022
Q3 		$1.01M Buy
15,456
+154
+1% +$11.2K 0.01% 252
2022
Q2 		$930K Buy
15,302
+565
+4% +$33.2K 0.01% 285
2022
Q1 		$925K Buy
14,737
+11,253
+323% +$707K 0.01% 289
2021
Q4 		$264K Buy
+3,484
New +$304K ﹤0.01% 509
2021
Q1 		– Sell
-10,084
Closed -$1.54M – 830
2020
Q4 		$1.54M Buy
+10,084
New +$1.19M 0.01% 288

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank Julius Baer & Co's CRSP Position: Q2 2026 in Review

Bank Julius Baer & Co increased its CRISPR Therapeutics (CRSP) stake by 2.5% in Q2 2026, buying an estimated $17.2K and bringing the position to 13,178 shares worth $740K. The position accounts for ﹤0.01% of the portfolio, ranked #424.

Bank Julius Baer & Co first reported a position in CRSP in Q4 2020 and has held it in 18 quarters since. The position peaked at $1.54M in Q4 2020. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Bank Julius Baer & Co held 13,178 shares of CRISPR Therapeutics worth $740K as of Q2 2026.
  • Bank Julius Baer & Co bought 326 CRISPR Therapeutics shares in Q2 2026, an estimated $17.2K.
  • CRISPR Therapeutics made up ﹤0.01% of Bank Julius Baer & Co's portfolio in Q2 2026, its #424 holding.
  • Bank Julius Baer & Co first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • Bank Julius Baer & Co's CRISPR Therapeutics position peaked at $1.54M in Q4 2020.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Bank Julius Baer & Co's 13F filing for Q2 2026, filed 10 Aug 2026.